Asset
ROCAKINOGENE SIFUPLASMID
Inovio Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03502785 | phase1_2 | completed | 2018-07-24 | 2025-05-09 | Inovio Pharmaceuticals | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma |
| NCT03491683 | phase1_2 | active_not_recruiting | 2018-05-31 | 2026-12-31 | Inovio Pharmaceuticals | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) |
| NCT02241369 | phase1 | completed | 2014-05-01 | 2018-09-01 | Inovio Pharmaceuticals | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies |
| NCT02464670 | phase1 | completed | 2015-05-01 | 2018-05-24 | Inovio Pharmaceuticals | Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers |
| NCT02960594 | phase1 | completed | 2014-12-01 | 2018-11-09 | Inovio Pharmaceuticals | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse |
FDA applications (0)
This company has no applications containing this asset.